

Top 10 Cardiac Diabetic PCD Pharma Franchise Companies in India - novalabcardiac
Table of Contents
ToggleHeart disease and diabetes aren’t niche concerns in India — they’re two of the most common reasons someone walks into a clinic these days. That alone has turned cardiac-diabetic into one of the steadiest, most in-demand categories in the whole PCD pharma business. For distributors and entrepreneurs eyeing this space, actually comparing Cardiac Diabetic PCD Pharma Franchise Companies in India properly — instead of grabbing the first name that shows up in a search — changes how the business performs down the line.
This guide covers how the model works, why the segment matters right now, ten companies worth researching, and the practical stuff — product range, monopoly terms, manufacturing standards, investment planning — that should actually drive the decision. Not brand recognition alone.
Strip it down and it’s a specialised version of the standard PCD (Propaganda Cum Distribution) model — just narrowed to products built for cardiovascular and diabetes management. Antihypertensives, anti-diabetics, cholesterol-lowering formulations, and combination products. Instead of juggling a general portfolio, a franchise partner here builds the whole business around one therapeutic focus.
At its core, the structure mirrors any PCD arrangement. The pharmaceutical company handles manufacturing or sourcing, branding, packaging, and supply. The franchise partner takes marketing and distribution within an agreed territory — building relationships with physicians, cardiologists, diabetologists, pharmacies, and the people who’ll actually prescribe and stock what’s being sold.
What makes this segment genuinely different is how those relationships behave. Cardiac and diabetic prescriptions tend to run long — once a physician trusts a brand for a chronic-care patient, that habit often holds for years. Compare that to general medicine, where a physician might switch brands without a second thought.
Cardiovascular disease numbers keep climbing across India, and chronic cardiac conditions usually mean years of medication, not weeks. That’s consistent, repeat demand — not the seasonal spikes you’d see in some other categories.
Diabetes prevalence has grown significantly over the decades, and type 2 diabetes specifically needs ongoing management — blood sugar control, monitoring, and often a combination of medications over the long haul. That sustained need is exactly what makes this category attractive for a business built on repeat orders rather than one-off sales.
Because these patients are usually on continuous therapy, a stock-out lands differently than it would with general medicine. A physician who can’t count on a steady supply from a brand just switches their patients to something else. Supply reliability isn’t a nice-to-have here — it’s genuinely central to whether the business works at all.
The companies below are an informational shortlist for further research — not an official or objective ranking. Current product portfolios, certifications, territory availability, and commercial terms should always be verified directly before making a decision.
Company Overview
Novalab Cardiac & Diabetic Care runs as a dedicated cardiac and diabetic division — built specifically around cardiovascular and anti-diabetic formulations, not tucked in as a side category within a general portfolio. The company positions itself as ISO 9001:2015 certified and invites franchise partners across Delhi, Haryana, Punjab, Himachal Pradesh, Uttarakhand, Jharkhand, Bihar, Kerala, and other regions.
1. Cardiac & Diabetic Product Portfolio:
The published range covers antihypertensives, antiarrhythmics, anti-diabetics, cholesterol management formulations, and antiplatelet products. Pretty much the core categories a cardiac-diabetic franchise partner needs to serve a physician’s full prescribing pattern — not just a slice of it.
2. Monopoly Franchise Opportunities:
Novalab Cardiac states it offers monopoly rights to franchise partners, letting them operate in a defined territory without internal competition from the same company. Get the exact boundary and conditions confirmed and documented before committing, as always.
3. Quality & Manufacturing Standards:
ISO 9001:2015 certification alongside GMP-WHO manufacturing standards shows up in the company’s published materials. Still worth requesting current documentation for the specific products you’re considering, rather than banking on a general certification claim alone.
4. Marketing & Business Support:
Novalab Cardiac describes providing marketing strategies and promotional support to its partners — meant to help a new partner establish presence faster than starting completely cold.
5. Distribution & Supply Support:
The company also states it provides distribution and customer support across its network. This matters more here than in most other segments, given how much continuous supply affects whether a cardiac-diabetic franchise can actually retain physician trust.
Dazzle Healthcare runs a broad pharmaceutical portfolio that includes cardiac, blood pressure, and diabetic categories alongside its wider range. ISO, GMP, and WHO certifications, plus monopoly-based franchise opportunities. Worth a look for partners who want cardiac-diabetic products plus access to a bigger multi-category catalogue on the side.
Biorise operates as a dedicated Cardiac-Diabetic PCD Pharma Franchise division of Biofield Pharma, which is ISO 9001:2015-certified. A specialised cardiac medicine range, plus promotional assistance aimed at helping franchise partners actually establish a brand presence in whatever territory they’re allocated.
Cardiancare positions itself specifically around cardiac and diabetic PCD franchise opportunities, with a notably large portfolio in this exact category. The focus stays on cardiovascular and diabetic conditions — not one category among many, but the whole business.
Cubic Lifesciences, based in Panchkula, carries a dedicated cardiac and diabetic range within a broader multi-category portfolio — products like Amlodipine and Atenolol combinations sit in there. For partners wanting cardiac-diabetic products with room to expand into tablets, syrups, or paediatric formulations down the line, that broader catalogue gives real flexibility.
Greystar Pharma operates in the PCD pharma franchise segment out of Chandigarh, with a portfolio spanning multiple therapeutic categories. Worth evaluating for its current cardiac-diabetic range and whatever territory’s actually open.
Founded in 2011 in Panchkula, Rezicure Pharmaceuticals built its franchise business specifically around cardiac and diabetic products, backed by GMP, GLP, and ISO-certified facilities in Derabassi, Punjab. The published range includes Voglibose and various amlodipine and telmisartan-based combinations.
Coniak Lifesciences, running since 2018 out of Panchkula, carries cardiac and diabetic formulations within a wider multi-range portfolio spanning tablets, injectables, and pediatric products. Confirm the current cardiac-diabetic catalogue directly — the company’s broader focus spans quite a few categories.
Ambit Bio-Medix, based in Ahmedabad, Gujarat, runs a dedicated Cardio Diabetic division with over 100 products in this category alone. ISO 9001 and WHO-GMP certified, and genuinely one of the more established PCD franchise names in Gujarat specifically.
Fortune Labs operates in the PCD pharma segment with cardiac-diabetic products among its focus areas, based out of Panchkula. Worth researching for its current product range and whatever territory’s open in this specific category.
| Company | Cardiac Range | Diabetic Range | Monopoly Opportunity | PCD Franchise |
|---|---|---|---|---|
| Novalab Cardiac | Dedicated | Dedicated | Yes | Yes |
| Dazzle Healthcare | Multi-Range | Multi-Range | Yes | Yes |
| Biorise (Biofield) | Dedicated | Dedicated | Yes | Yes |
| Cardiancare | Dedicated | Dedicated | Yes | Yes |
| Cubic Lifesciences | Multi-Range | Multi-Range | Yes | Yes |
| Greystar Pharma | Multi-Range | Multi-Range | Yes | Yes |
| Rezicure Pharmaceuticals | Dedicated | Dedicated | Yes | Yes |
| Coniak Lifesciences | Multi-Range | Multi-Range | Yes | Yes |
| Ambit Bio-Medix | Dedicated | Dedicated | Yes | Yes |
| Fortune Labs | Multi-Range | Multi-Range | Verify Directly | Yes |
ACE inhibitors, ARBs, and calcium channel blockers are used to manage high blood pressure. A category with steady, long-term demand, simply because hypertension has become so common.
Standalone and combination therapies for blood sugar management, spanning first-line options through to more advanced treatments for type 2 diabetes.
Formulations like clopidogrel and aspirin combinations are used to cut clotting risk in patients managing cardiovascular risk factors.
Statins and related lipid-lowering formulations are often prescribed alongside other cardiac medications for patients juggling multiple risk factors at once.
Beta-blockers and other supportive cardiac medications used across a range of cardiovascular conditions, heart failure and angina management included.
Products targeting glucose control specifically — including newer categories like Bempedoic Acid-based formulations that have entered the market more recently.
Fixed-dose combinations pairing antihypertensives with diabetic management drugs, simplifying multi-drug regimens for patients dealing with both conditions at once — genuinely practical, given how often cardiac and diabetic conditions show up together in the same patient.
This lines up with Novalab Cardiac & Diabetic Care’s current published portfolio positioning, which spans several of these categories under one specialised division.
| Brand Name | Composition | Packing |
|---|---|---|
| AMIOCRED-100 | Amiodarone 100mg | 10×10 (Blister) |
| BENKOK-4 | Benidipine 4mg | 10×10 (Alu-Alu) |
| BISOCRED-2.5 | Bisoprolol Fumarate 2.5mg | 10×15 (Blister) |
| BEMIOVA-180 | Bempedoic Acid 180mg | 10×7 (Alu-Alu) |
| CARVECRED-6.25 | Carvedilol 6.25mg | 10×15 (Blister) |
| CLOPIDEYS-A 75 | Clopidogrel 75mg | 10×10 (Alu-Alu) |
Does the portfolio genuinely cover both cardiac and diabetic categories deep enough to serve a physician’s full prescribing pattern? Or is it just a handful of token products?
Ask for current manufacturing and quality certificates tied to the specific products you’re actually considering — not a general company-wide claim you’re expected to just accept.
Get the exact geographical boundary, covered products, duration, and renewal conditions documented in writing before accepting any monopoly arrangement. In writing, not over a call.
Weigh net rates alongside taxes, freight, and payment conditions. The headline price rarely tells the whole story on its own.
Given how much continuous therapy matters here, ask specifically about repeat-order reliability and normal dispatch timelines — not just whether the opening order’s available.
Confirm what’s actually included — visual aids, product literature, product cards — rather than assuming it matches whatever the general marketing claims say.
Read the actual contract closely. Territory, product coverage, minimum purchase requirements, termination clauses — this is exactly where problems hide if nobody bothers reading carefully.
Generally, it means a company won’t appoint a second franchise partner for the same products within your agreed territory. Not protection from every competing brand in the market — just an agreement specific to that one company’s own appointments.
Physician relationships in this segment take real time to build. A clearly defined monopoly territory protects that time investment more than it would in a general retail-focused franchise, where that kind of relationship-building matters less.
Confirm the exact geographical boundary, which products actually fall under the exclusivity, how long it runs, and what could affect renewal later — all in writing. A phone call doesn’t count.
Common requirements: an applicable Drug Licence, GST registration where required, PAN, identity and business address proof, and a written franchise agreement. Confirm current licensing requirements with the relevant drug-control authority before starting operations — requirements shift depending on business structure and activity.
There’s no fixed or universal investment figure here, and anyone quoting you a flat number is oversimplifying. The actual requirement depends on several moving pieces:
Skip chasing a generic “low investment” figure. Request a product-wise quotation from your shortlisted company and build your budget around the actual portfolio you’re selecting.
Novalab Cardiac runs as a dedicated division, not a side category bolted onto something bigger — which means the product range is actually built around this segment’s specific needs.
The published portfolio spans antihypertensives, antiarrhythmics, cholesterol management, and anti-diabetic formulations — room for franchise partners to serve a broad prescribing pattern from one supplier instead of several.
Novalab Cardiac states it offers monopoly rights to its franchise partners, subject to territory availability and current terms. Confirm these directly for your specific region before assuming anything.
The company describes providing marketing strategies and distribution support to its network — meant to help new partners establish their presence faster than they otherwise would.
Novalab Cardiac also states it provides customer support alongside product supply. Worth confirming exactly what that actually covers for your specific franchise arrangement before signing anything — these are the company’s own stated positions, and as with any franchise company, current certifications, manufacturing documentation, and support terms are worth verifying directly rather than taken on faith from published claims alone.
Cardiovascular disease and diabetes aren’t trending downward in India — if anything, the numbers keep climbing. For franchise partners, that means this category should stay resilient even when other parts of the pharma market wobble. Long-term growth will come down less to how many products sit in a catalogue and more to physician relationships, consistent supply, and how well a partner actually develops their territory over time.
A Cardiac Diabetic PCD Pharma Franchise in India carries genuine long-term potential, backed by a segment whose demand shows no sign of slowing down anytime soon. But picking the right company takes more than comparing brand names on a list — product range, manufacturing documentation, monopoly terms, supply reliability, and realistic investment planning all deserve a proper look before anyone commits money.
Novalab Cardiac & Diabetic Care is worth considering, given its dedicated focus on exactly this segment, its stated monopoly-based opportunities, and its published cardiac-diabetic product range. As with every company on this list, confirm the latest product catalogue, current certification documentation, and territory availability directly before entering into an agreement.
Ans. Product range relevance, manufacturing and quality documentation, monopoly territory terms, pricing, supply consistency, promotional support, and the actual franchise agreement — not just brand reputation on its own.
Ans. A specialised PCD franchise arrangement focused on cardiovascular and diabetes management products, where a franchise partner markets and distributes a company’s cardiac-diabetic portfolio within an agreed territory.
Ans. Typically antihypertensives, anti-diabetics, cholesterol management formulations, antiplatelet and anticoagulant products, and combination cardiac-diabetic formulations — depending on the company’s current catalogue.
Ans. Generally, agreed marketing or distribution rights for specified products within a defined territory. It stops the company from appointing a second partner for those same products in that area — it’s not freedom from competing companies altogether.
Ans. An applicable Drug Licence, GST registration where required, PAN, identity and business address proof, and a written franchise agreement — though exact requirements shift by business structure.
Ans. Build a real comparison across product range, manufacturing documentation, pricing, MOQ, supply reliability, monopoly terms, and promotional support. Don’t lean on a single factor like advertised margins.
Ans. Yes, but relevance beats sheer size every time. A smaller range that genuinely matches your target physician network’s prescribing patterns outperforms a large catalogue with limited local relevance.
Ans. Look at existing physician and hospital networks, local competition, and your actual ability to service the area consistently. A smaller, well-covered territory usually outperforms a bigger one you can’t properly manage.
Ans. Territory boundaries, product coverage, minimum purchase requirements, duration, renewal conditions, and termination clauses. Read these closely — this is exactly where disputes tend to originate later.
This will close in 0 seconds